AssetMark Inc
AKRO

AssetMark Inc’s Akero Therapeutics AKRO Stock Holding History

AssetMark Inc’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,276
Closed -$60.6K – 3373
2025
Q3 		$60.6K Sell
1,276
-163
-11% -$7.89K ﹤0.01% 1570
2025
Q2 		$76.8K Buy
1,439
+870
+153% +$39.5K ﹤0.01% 1431
2025
Q1 		$23K Buy
+569
New +$24.1K ﹤0.01% 1671

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AssetMark Inc's AKRO Position: Q4 2025 in Review

AssetMark Inc sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,276 shares — an estimated $60.6K sold.

AssetMark Inc first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $76.8K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • AssetMark Inc reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AssetMark Inc sold 1,276 Akero Therapeutics shares in Q4 2025, an estimated $60.6K.
  • AssetMark Inc first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
  • AssetMark Inc's Akero Therapeutics position peaked at $76.8K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on AssetMark Inc's 13F filing for Q4 2025, filed 23 Jan 2026.